Medically reviewed by Drugs.com. Last updated on Jul 30, 2020.
(SEF tay zi deem)
Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product
Solution, Intravenous, as sodium [strength expressed as base]:
Tazicef: 1 g/50 mL (50 mL)
Solution, Intravenous, as sodium [strength expressed as base, preservative free]:
Fortaz in D5W: 1 g (50 mL [DSC]); 2 g (50 mL [DSC])
Solution Reconstituted, Injection:
Fortaz: 500 mg (1 ea); 1 g (1 ea); 2 g (1 ea [DSC]); 6 g (1 ea [DSC])
Solution Reconstituted, Injection [preservative free]:
Tazicef: 1 g (1 ea); 2 g (1 ea); 6 g (1 ea)
Generic: 1 g (1 ea); 2 g (1 ea); 6 g (1 ea)
Solution Reconstituted, Intravenous:
Fortaz: 1 g (1 ea [DSC]); 2 g (1 ea)
Solution Reconstituted, Intravenous [preservative free]:
Tazicef: 1 g (1 ea); 2 g (1 ea)
Generic: 1 g (1 ea); 2 g (1 ea)
Brand Names: U.S.
- Fortaz in D5W [DSC]
- Antibiotic, Cephalosporin (Third Generation)
Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs), which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested.
Widely throughout the body including bone, bile, skin, CSF (higher concentrations achieved when meninges are inflamed), endometrium, heart, pleural and lymphatic fluids.
Preterm neonates <32 weeks GA (van den Anker 1995):
PNA 3 days: 0.363 ± 0.059 L/kg.
PNA 10 days: 0.292 ± 0.044 L/kg.
Infants and Children ≤2 years: Steady state: Median: 0.4 L/kg (range: 0.34 to 0.46) L/kg (Shi 2018).
Urine (80% to 90% as unchanged drug)
Time to Peak
Serum: IM: ~1 hour
Preterm neonates <32 weeks GA (van den Anker 1995):
PNA 3 days: 8.7 ± 2.8 hours.
PNA 10 days: 5 ± 0.9 hours.
Adult: 1 to 2 hours, significantly prolonged with renal impairment.
Use: Labeled Indications
Bloodstream infection (gram-negative bacteremia): Treatment of bloodstream infection caused by Pseudomonas aeruginosa, Klebsiella spp., Haemophilus influenzae, Escherichia coli, Serratia spp., Streptococcus pneumoniae, and Staphylococcus aureus (methicillin-susceptible strains).
Bone and joint infections: Treatment of bone and joint infections caused by P. aeruginosa, Klebsiella spp., Enterobacter spp., and S. aureus (methicillin-susceptible strains).
CNS infections: Treatment of CNS infections, including meningitis, caused by H. influenzae and Neisseria meningitidis. Ceftazidime has also been used successfully in cases of meningitis due to P. aeruginosa and S. pneumoniae.
Empiric therapy in immunocompromised patients: Empiric treatment of infections in immunocompromised patients.
Gynecologic infections: Treatment of endometritis, pelvic cellulitis, and other infections of the female genital tract caused by E. coli.
Intra-abdominal infections: Treatment of peritonitis caused by E. coli, Klebsiella spp., and S. aureus (methicillin-susceptible strains) and polymicrobial intra-abdominal infections caused by aerobic and anaerobic organisms and some Bacteroides spp. (many isolates of Bacteroides fragilis are resistant).
Lower respiratory tract infections: Treatment of lower respiratory tract infections, including pneumonia, caused by P. aeruginosa and other Pseudomonas spp.; H. influenzae, including ampicillin-resistant isolates; Klebsiella spp.; Enterobacter spp.; Proteus mirabilis; E. coli; Serratia spp.; Citrobacter spp.; S. pneumoniae; and S. aureus (methicillin-susceptible strains).
Skin and soft tissue infections: Treatment of skin and soft tissue infections caused by P. aeruginosa; Klebsiella spp.; E. coli; Proteus spp., including P. mirabilis and indole-positive Proteus; Enterobacter spp.; Serratia spp.; S. aureus (methicillin-susceptible strains); and Streptococcus pyogenes (group A beta-hemolytic streptococci).
Urinary tract infections: Treatment of complicated and uncomplicated urinary tract infections caused by P. aeruginosa; Enterobacter spp.; Proteus spp., including P. mirabilis and indole-positive Proteus; Klebsiella spp.; and E. coli.
Off Label Uses
Cystic fibrosis, acute pulmonary exacerbation
Data from 2 randomized, multicenter trials support the use of ceftazidime in combination with tobramycin for the treatment of acute pulmonary exacerbations of cystic fibrosis [Hubert 2009], [Latzin 2008]. Clinical experience also suggests the utility of ceftazidime as part of an appropriate combination regimen for this condition [Simon 2019], [Zobell 2013].
Diabetic foot infection, moderate to severe
Based on the Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections, ceftazidime is an effective and recommended agent as part of an appropriate combination regimen for the treatment of moderate to severe diabetic foot infection. Clinical experience also suggests the utility of ceftazidime in the treatment of this condition [Weintrob 2019].
Data from a randomized trial of immediate vitrectomy and intravenous antibiotics for the treatment of postoperative bacterial endophthalmitis support the use of ceftazidime in this condition [Kelsey 1995].
Melioidosis (Burkholderia pseudomallei infection)
Melioidosis is a worldwide subtropical and tropical bacterial disease caused by contact with Burkholderia pseudomallei-contaminated water or soil [Lipsitz 2012]. A US Department of Health and Human Services workshop on treatment of and postexposure prophylaxis for B. pseudomallei and Burkholderia mallei infection supports the use of ceftazidime as a first-line agent for initial treatment of melioidosis [Lipsitz 2012].
Peritonitis, treatment (peritoneal dialysis patients)
Based on the International Society for Peritoneal Dialysis peritonitis recommendations: 2016 update on prevention and treatment, ceftazidime is effective and recommended in the treatment of peritonitis associated with peritoneal dialysis.
Hypersensitivity to ceftazidime, other cephalosporins, penicillins, other beta-lactam antibiotics, or any component of the formulation
Usual dosage range: Note: Infusion method: Dosing is presented in the indication-specific dosing based on the traditional infusion method over 30 minutes, unless otherwise specified.
Traditional intermittent infusion method: IV: 1 to 2 g every 8 hours infused over 30 minutes. For treatment of very severe life-threatening infections, especially in immunocompromised hosts: 2 g every 8 hours (manufacturer's labeling).
Extended infusion method (off-label method): IV: 2 g every 8 hours infused over 3 to 4 hours; may give first dose over 30 minutes, especially when rapid attainment of therapeutic drug concentrations is desired (eg, sepsis) (Ram 2018; SCCM [Rhodes 2017]; Turner 2015).
Continuous infusion method (off-label method): IV: 6 g infused over 24 hours (Bulitta 2010; Lipman 1999; Lipsitz 2012); may give first dose of 2 g over 30 minutes, especially when rapid attainment of therapeutic drug concentrations is desired (eg, sepsis) (SCCM [Rhodes 2017]).
Extended and continuous infusion methods are based largely on pharmacokinetic and pharmacodynamic modeling data; clinical efficacy data are limited (Bulitta 2010; Koomanachai 2010; Lipman 1999; Ram 2018; Turner 2015).
Bloodstream infection (gram-negative bacteremia): For empiric therapy of known or suspected gram-negative bacteria (including Pseudomonas aeruginosa) or pathogen-directed therapy for organisms resistant to other agents:
IV: 2 g every 8 hours; for empiric therapy in patients with neutropenia, severe burns, sepsis, or septic shock, give as part of an appropriate combination regimen (Kanj 2020a; Moehring 2019; SCCM [Rhodes 2017]). Note: Some experts prefer the extended or continuous infusion method in critical illness or if treating a susceptible organism with an elevated minimum inhibitory concentration (Moehring 2019; SCCM [Rhodes 2017]).
Duration of therapy: Usual duration is 7 to 14 days depending on source, pathogen, extent of infection, and clinical response (Moehring 2019); a 7-day duration is recommended for patients with uncomplicated Enterobacteriaceae infection who respond appropriately to antibiotic therapy (Chotiprasitsakul 2018; Moehring 2019; Yahav 2018). Note: If neutropenic, extend treatment until afebrile for 2 days and neutrophil recovery (ANC ≥500 cells/mm3 and increasing) (IDSA [Freifeld 2011]). For P. aeruginosa bacteremia in neutropenic patients, some experts treat for a minimum of 14 days and until recovery of neutrophils (Kanj 2019b).
Antibiotic lock technique (catheter-salvage strategy): Note: For infections caused by susceptible organisms when the catheter cannot be removed; use in addition to systemic antibiotics.
Intracatheter: Prepare lock solution to final concentration of ceftazidime 5 to 10 mg/mL; may be combined with heparin (Allon 2009; Poole 2004; Vercaigne 2000). The ceftazidime concentration may vary by institution, catheter type, and whether heparin is utilized; solutions with heparin are preferred. Additional ceftazidime concentrations have been studied (IDSA [Mermel 2009]; Rijnders 2005). Instill into each lumen of the catheter access port using a volume sufficient to fill the catheter (2 to 5 mL) with a dwell time of up to 72 hours, depending on frequency of catheter use. Withdraw lock solution prior to catheter use; replace with fresh ceftazidime lock solution after catheter use. Antibiotic lock therapy is given for the same duration as systemic antibiotics (Girand 2020; IDSA [Mermel 2009]; Poole 2004).
Cystic fibrosis, acute pulmonary exacerbation (off-label use): For empiric or targeted therapy of P. aeruginosa or other gram-negative bacilli:
Traditional intermittent infusion method: IV: Usual dose: 2 g every 6 to 8 hours or 150 to 200 mg/kg/day divided every 6 to 8 hours (Simon 2019); doses up to 200 to 400 mg/kg/day divided every 6 to 8 hours (maximum: 12 g daily) have also been recommended (Latzin 2008; Zobell 2013).
Extended infusion method: IV: 2 g every 8 hours over 3 to 4 hours (Bulitta 2010; Thompson 2016).
Continuous infusion method: IV: Usual dose: 6 g over 24 hours (Bulitta 2010); doses up to 100 to 200 mg/kg/day (maximum: 12 g daily) have also been studied (Hubert 2009; Zobell 2013).
Duration of therapy: Duration is usually 10 days to 3 weeks or longer based on clinical response (Flume 2009; Simon 2019).
Diabetic foot infection, moderate to severe (off-label use): IV: 1 to 2 g every 8 hours. For empiric therapy, give as part of an appropriate combination regimen. If at risk for P. aeruginosa (eg, significant water exposure, macerated wound) or P. aeruginosa is cultured, use 2 g every 8 hours. Duration (which may include oral step-down therapy) is usually 2 to 4 weeks in the absence of osteomyelitis (IDSA [Lipsky 2012]; Weintrob 2019).
Endophthalmitis, bacterial (empiric therapy) (off-label use): Intravitreal: 2 to 2.25 mg/0.1 mL NS or sterile water in combination with vancomycin (Durand 2020; Jackson 2003; Roth 1997); a repeat dose(s) may be considered at 24 to 48 hours based on culture result, severity of infection, and response to treatment (Durand 2020).
Intra-abdominal infection, health care-associated or high-risk community-acquired infection: Note: For community-acquired infection, reserve for severe infection or patients at high risk of adverse outcome and/or resistance (Barshak 2020; SIS/IDSA [Solomkin 2010]):
Cholecystitis, acute: IV: 2 g every 8 hours; continue for 1 day after gallbladder removal or until clinical resolution in patients managed nonoperatively (Gomi 2018; SIS [Mazuski 2017]; SIS/IDSA [Solomkin 2010]; Vollmer 2019).
Other intra-abdominal infections (eg, cholangitis, perforated appendix, diverticulitis, intra-abdominal abscess): IV: 2 g every 8 hours in combination with metronidazole and, when appropriate, other agents. Total duration of therapy (which may include oral step-down therapy) is 4 to 7 days following adequate source control (Barshak 2020; SIS [Mazuski 2017]; SIS/IDSA [Solomkin 2010]); for infections managed without surgical or percutaneous intervention, a longer duration may be necessary (Barshak 2020; Pemberton 2019). Note: For patients who are critically ill or are at high risk for infection with drug-resistant pathogens, some experts favor the extended or continuous infusion method (Barshak 2020; WSES [Sartelli 2017]).
Intracranial abscess (brain abscess, intracranial epidural abscess) and spinal epidural abscess: For empiric or directed therapy in patients at risk for P. aeruginosa or other resistant gram-negative bacteria (eg, neurosurgical or immunocompromised patients):
IV: 2 g every 8 hours as part of an appropriate combination regimen; duration generally ranges from 4 to 8 weeks for brain abscess and spinal epidural abscess, and 6 to 8 weeks for intracranial epidural abscess (Bodilsen 2018; Sexton 2019a; Sexton 2019b; Southwick 2020).
Melioidosis (Burkholderia pseudomallei infection) (off-label use): Initial intensive therapy: IV: 2 g every 6 to 8 hours (Lipsitz 2012; White 1989; Wiersinga 2012) or 2 g as a single dose followed by 6 g daily by continuous infusion. Duration is 10 to 14 days, although a longer duration may be necessary depending on disease severity and site of infection (Lipsitz 2012). Some experts recommend adding sulfamethoxazole and trimethoprim for patients with focal disease of the CNS, prostate, bone, joint, skin, or soft tissue (Currie 2019). Note: Following the course of parenteral therapy, eradication therapy with oral antibiotics for ≥12 weeks is recommended (Lipsitz 2012).
Meningitis, bacterial: As a component of empiric therapy for health care-associated infection or as pathogen-specific therapy for gram-negative bacteria resistant to other antibiotics (eg, P. aeruginosa):
IV: 2 g every 8 hours; for empiric therapy, use in combination with vancomycin (IDSA [Tunkel 2004]; IDSA [Tunkel 2017]). Treatment duration for gram-negative bacilli is a minimum of 10 to 14 days, although some experts recommend ≥21 days (Hasbun 2020; IDSA [Tunkel 2017]).
Neutropenic fever, high-risk cancer patients (empiric therapy): Note: High-risk patients are those expected to have an ANC ≤100 cells/mm3 for >7 days or an ANC ≤100 cells/mm3 for any expected duration if there are ongoing comorbidities (eg, sepsis, mucositis, significant hepatic or renal dysfunction) (IDSA [Freifeld 2011]); some experts use an ANC cutoff of <500 cells/mm3 to define high-risk patients (Wingard 2019).
IV: 2 g every 8 hours as part of an appropriate combination regimen; continue until afebrile for ≥48 hours and resolution of neutropenia (ANC ≥500 cells/mm3 and increasing) or standard duration for the specific infection identified, if longer than the duration for neutropenia (IDSA [Freifeld 2011]; Wingard 2019). Note: Some experts prefer the extended infusion method, particularly in those who are critically ill (SCCM [Rhodes 2017]; Wingard 2019).
Osteomyelitis and/or discitis: Note: For empiric therapy or pathogen-directed therapy for gram-negative bacteria resistant to other antibiotics (eg, P. aeruginosa):
IV: 2 g every 8 hours, generally for ≥6 weeks; for empiric therapy, use as part of an appropriate combination regimen (IDSA [Berbari 2015]; Osmon 2019).
Peritonitis, treatment (peritoneal dialysis patients) (off-label use): As a component of empiric therapy or as pathogen-directed therapy for gram-negative bacteria resistant to other antibiotics (eg, P. aeruginosa): Note: Intraperitoneal administration is preferred to IV administration (ISPD [Li 2016]). Consider a 25% dose increase in patients with significant residual renal function (urine output >100 mL/day) (ISPD [Li 2010]; ISPD [Li 2016]; Mancini 2018; Szeto 2018).
Continuous ambulatory peritoneal dialysis: 1 to 1.5 g added to one exchange once daily (allow to dwell ≥6 hours) (ISPD [Li 2016]).
Automated peritoneal dialysis: 20 mg/kg once daily administered in the longest dwell (Kim 2011).
Continuous (with every exchange) (dose is per liter of dialysate): Intraperitoneal: Loading dose: 500 mg/L of dialysate with first dialysate exchange; maintenance dose: 125 mg/L of dialysate with each subsequent dialysate exchange (ISPD [Li 2016]).
Community-acquired pneumonia: For empiric therapy of inpatients at risk of infection with a resistant gram-negative pathogen(s), including P. aeruginosa:
IV: 2 g every 8 hours as part of an appropriate combination regimen. Total duration (which may include oral step-down therapy) is for a minimum of 5 days; a longer course may be required for P. aeruginosa infection. Patients should be clinically stable with normal vital signs prior to discontinuation (IDSA/ATS [Metlay 2019]).
Hospital-acquired or ventilator-associated pneumonia: For empiric therapy or pathogen-specific therapy of resistant gram-negative pathogen(s), including P. aeruginosa:
IV: 2 g every 8 hours as part of an appropriate combination regimen. Duration varies based on disease severity and response to therapy; treatment is typically given for 7 days (IDSA/ATS [Kalil 2016]), but a longer course may be required for severe or complicated infection or for P. aeruginosa infection (Kanj 2019c). Note: Some experts prefer the extended or continuous infusion method, particularly in those who are critically ill (Kim 2009; Klompas 2019; SCCM [Rhodes 2017]).
Prosthetic joint infection (alternative agent): As a component of empiric therapy or as pathogen-directed therapy for gram-negative bacteria resistant to other antibiotics (eg, P. aeruginosa):
IV: 2 g every 8 hours; duration varies but is generally 4 to 6 weeks for patients who undergo resection arthroplasty (Berbari 2019; IDSA [Osmon 2013]).
Septic arthritis: As a component of empiric therapy or as pathogen-directed therapy for gram-negative bacteria resistant to other antibiotics (eg, P. aeruginosa):
IV: 2 g every 8 hours; for empiric therapy, use in combination with vancomycin. Total treatment duration is 3 to 4 weeks (in the absence of osteomyelitis), including oral step-down therapy (Goldenberg 2019).
Skin and soft tissue infection, moderate to severe: As empiric therapy or pathogen-directed therapy in patients with or at risk for gram-negative bacteria resistant to other antibiotics (eg, P. aeruginosa):
IV: 2 g every 8 hours. Usual duration is 10 to 14 days based on response to therapy (Hoepelman 1993; Kanj 2019d). Note: For burn-associated infections, some experts suggest giving ceftazidime with an aminoglycoside (Kanj 2019d).
Urinary tract infection, complicated (including pyelonephritis): IV: 1 to 2 g every 8 hours; use 2 g every 8 hours if P. aeruginosa is suspected (Bader 2017; Hoepelman 1993; Kanj 2019e). When used for empiric therapy, use alone or in combination with other appropriate agents. Switch to an appropriate oral regimen once patient has improvement in symptoms, if culture and susceptibility results allow. Duration of therapy depends on the antimicrobial chosen to complete the regimen and ranges from 5 to 14 days (Hooton 2019).
Refer to adult dosing.
General dosing, susceptible infection (Red Book [AAP 2018]): IM, IV: Infants, Children, and Adolescents:
Non-Pseudomonas spp. infections: 90 to 150 mg/kg/day divided every 8 hours; maximum daily dose: 6 g/day.
Pseudomonas spp. infections:
Mild to moderate infections: 90 to 150 mg/kg/day divided every 8 hours; maximum daily dose: 6 g/day.
Severe infections: 200 to 300 mg/kg/day divided every 8 hours; maximum daily dose: 12 g/day.
Cystic fibrosis, lung infection caused by Pseudomonas spp. or other susceptible gram negative organisms:
Traditional intermittent infusion method:
Infants, Children, and Adolescents: IV: 200 to 400 mg/kg/day divided every 6 to 8 hours; maximum daily dose: 12 g/day (Latzin 2008; Zobell 2013; Zobell 2017). Doses of 150 mg/kg/day in divided doses every 8 hours have also been reported (Reed 1987).
Continuous infusion method:
Children ≥5 years and Adolescents: IV: 100 to 200 mg/kg/day infused continuously over 24 hours; maximum daily dose: 12 g/day (Hubert 2009; Rappaz 2000; Riethmueller 2009; Zobell 2013; Zobell 2017). May give an initial loading dose (60 mg/kg; maximum dose: 2,000 mg/dose) once before starting the continuous infusion if rapid attainment of therapeutic drug concentrations is desired (eg, sepsis) (Guilhaumou 2019; Hubert 2009).
Endocarditis, treatment: Children and Adolescents: IV: 100 to 150 mg/kg/day divided every 8 hours; maximum daily dose: 4,000 mg/day; use in combination with gentamicin or vancomycin and gentamicin (plus rifampin if prosthetic material is present) depending on the cause of infection (AHA [Baltimore 2015]).
Intra-abdominal infections, complicated: Infants, Children, and Adolescents: IV: 50 mg/kg/dose every 8 hours in combination with metronidazole; maximum daily dose: 6 g/day (IDSA [Solomkin 2010]).
Meningitis, including healthcare-associated ventriculitis/meningitis: Infants, Children, and Adolescents: IV: 150 to 200 mg/kg/day in divided doses every 8 hours; maximum daily dose: 6 g/day; use in combination with vancomycin for empiric coverage (IDSA [Tunkel 2004]; IDSA [Tunkel 2017]).
Neutropenic fever, treatment (known susceptible gram-negative bacteria): Limited data available: Note: Ceftazidime is not recommended empiric management of neutropenic fever in high-risk children (Lehrnbecher 2012).
Traditional intermittent infusion method: Infants ≥6 months, Children, and Adolescents: IV: 100 to 150 mg/kg/day divided every 8 hours in combination with an aminoglycoside; maximum daily dose: 6 g/day (Corapçioglu 2005; Kamonrattana 2019; Laoprasopwattana 2007).
Continuous infusion method: Infants ≥6 months, Children, and Adolescents: IV: Loading dose: 60 to 100 mg/kg; maximum loading dose: 2,000 mg/dose; followed by 100 to 200 mg/kg/day infused continuously over 24 hours; maximum daily dose: 6 g/day (Cojutti 2019; Dalle 2002).
Peritonitis (peritoneal dialysis): Infants, Children, and Adolescents: Intraperitoneal:
Intermittent: 20 mg/kg/dose every 24 hours in the long dwell (ISPD [Warady 2012]); in adults, intermittent: 1,000 to 1,500 mg every 24 hours per exchange in the long dwell (≥6 hours) (Li 2010).
Continuous: Loading dose: 500 mg per liter of dialysate; maintenance dose: 125 mg per liter (ISPD [Warady 2012]).
Urinary tract infection: Infants, Children, and Adolescents: IV: 100 to 150 mg/kg/day divided every 8 hours (AAP 2011; Balighian 2018).
IM: Using SWFI, bacteriostatic water for injection, lidocaine 0.5%, or lidocaine 1%, reconstitute the 500 mg vials with 1.5 mL or the 1 g vials with 3 mL; final concentration of ~280 mg/mL.
IV: Reconstitute intact vials as follows (Note: After reconstitution, may dilute further with a compatible solution [eg, D5W, NS] to administer via IV infusion):
500 mg vial: Reconstitute with 5.3 mL SWFI (final concentration ~100 mg/mL).
1 g vial: Reconstitute with 10 mL SWFI (final concentration may vary; refer to manufacturer’s labeling).
2 g vial: Reconstitute with 10 mL SWFI (final concentration may vary; refer to manufacturer’s labeling).
6 g vial: Reconstitute with 26 mL SWFI (final concentration ~200 mg/mL) or 56 mL SWFI (final concentration ~100 mg/mL).
Duplex container: Unlatch side tab, unfold, remove foil strip from drug chamber. Point set port in downward direction, fold container just below the diluent meniscus, and squeeze the diluent chamber until the seal between the diluent and drug powder opens. Agitate until dissolved.
IM: Ceftazidime can be administered deep IM into large mass muscle.
IV: Can be administered IV push over 3 to 5 minutes or by IV intermittent infusion over 15 to 30 minutes.
Intravitreal: Ceftazidime may be administered intravitreally as 2 to 2.25 mg/0.1 mL NS in combination with vancomycin (separate syringes) (Jackson 2003; Roth 1997).
Intraperitoneal: Intraperitoneal administration may be used in conjunction with IV use for systemic infections if continuous peritoneal dialysis is used (added to the dialysate in each exchange). Intraperitoneal administration alone may also be used for the treatment of peritonitis and added to the dialysate in intermittent (added to the longest dwell time per day) or continuous (loading dose, followed by a maintenance dose per liter of exchange) peritoneal dialysis.
Inhalation for nebulization (off-label use/route): Use with standard jet nebulizer connected to an air compressor; administer 1,000 mg diluted in 8 mL NS with mouthpiece or face mask (Orriols 1999).
Some products may contain sodium.
Vials: Store intact vials at 20°C to 25°C (68°F to 77°F). Protect from light. Refer to manufacturer's labeling for specific storage instructions for reconstituted solution and solution further diluted for IV infusion (varies by diluent).
Duplex container: Store unactivated containers at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Protect from light. Do not freeze. Unactivated duplex containers with foil strip removed from the drug chamber must be protected from light and used within 7 days at room temperature. Once activated, must be used within 12 hours if stored at room temperature or within 3 days if stored under refrigeration.
Premixed frozen solution: Store at -20°C (-4°F). Thawed solution is stable for 8 hours at room temperature or for 3 days under refrigeration; do not refreeze.
Aminoglycosides: Cephalosporins may enhance the nephrotoxic effect of Aminoglycosides. Cephalosporins may decrease the serum concentration of Aminoglycosides. Monitor therapy
BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). Avoid combination
BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). Monitor therapy
Chloramphenicol (Systemic): May diminish the therapeutic effect of CefTAZidime. Management: Consider using a different combination of antimicrobials, especially if bactericidal activity is desired. If these agents are combined, monitor for reduced antimicrobial effectiveness and/or therapeutic failure. Consider therapy modification
Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics. Avoid combination
Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. Monitor therapy
Probenecid: May increase the serum concentration of Cephalosporins. Monitor therapy
Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate. Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic. Consider therapy modification
Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected. Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents. Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents. Consider therapy modification
Vitamin K Antagonists (eg, warfarin): Cephalosporins may enhance the anticoagulant effect of Vitamin K Antagonists. Monitor therapy
Positive direct Coombs', false-positive urinary glucose test using cupric sulfate (Benedict's solution, Clinitest®, Fehling's solution), false-positive serum or urine creatinine with Jaffé reaction
1% to 10%:
Dermatologic: Pruritus (<2%), skin rash (<2%)
Endocrine & metabolic: Increased lactate dehydrogenase (6%), increased gamma-glutamyl transferase (5%)
Gastrointestinal: Diarrhea (1%)
Hematologic & oncologic: Eosinophilia (8%), positive direct Coombs test (4%; without hemolysis), thrombocythemia (2%)
Hepatic: Increased serum ALT (7%), increased serum AST (6%), increased serum alkaline phosphatase (4%)
Hypersensitivity: Hypersensitivity reactions (2%)
Local: Inflammation at injection site (1%), injection site phlebitis (1%)
Miscellaneous: Fever (<2%)
Frequency not defined:
Central nervous system: Seizure
Hematologic & oncologic: Agranulocytosis, leukopenia, lymphocytosis, neutropenia, thrombocytopenia
Renal: Increased blood urea nitrogen, increased serum creatinine
<1%, postmarketing, and/or case reports: Abdominal pain, anaphylaxis (severe in rare instances, including cardiopulmonary arrest), angioedema, candidiasis, Clostridioides (formerly Clostridium) difficile-associated diarrhea, dizziness, erythema multiforme, headache, hemolytic anemia, hyperbilirubinemia, jaundice, nausea, pain at injection site, paresthesia, renal insufficiency, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria, vaginitis, vomiting
Concerns related to adverse effects:
• Elevated INR: May be associated with increased INR, especially in nutritionally deficient patients, prolonged treatment, hepatic or renal disease. Monitor INR during treatment if patient is at risk; administer vitamin K as clinically indicated.
• Hemolytic anemia: Immune-mediated hemolytic anemia, sometimes fatal, has been observed in patients receiving cephalosporins, including ceftazidime. If a patient develops anemia while on ceftazidime, discontinue treatment until the etiology is determined.
• Hypersensitivity: Hypersensitivity and anaphylaxis have been reported in patients receiving beta-lactam drugs. Use caution in patients with a history of hypersensitivity to penicillins or other beta-lactams; use is contraindicated in patients with cephalosporin allergy (according to the manufacturer). If severe hypersensitivity occurs, discontinue immediately and institute supportive emergency measures.
• Neurotoxicity: High ceftazidime levels in patients with renal insufficiency can lead to seizures, nonconvulsive status epilepticus, encephalopathy, coma, asterixis, myoclonia, and neuromuscular excitability. Adjust dosage based on renal function.
• Superinfection: Prolonged use may result in fungal or bacterial superinfection, including Clostridioides (formerly Clostridium) difficile-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed >2 months postantibiotic treatment.
• GI disease: Use with caution in patients with a history of GI disease, especially colitis.
• Renal impairment: Use with caution in patients with renal impairment; dosage adjustment recommended.
• Seizure disorders: Use with caution in patients with a history of seizure disorder; high levels, particularly in the presence of renal impairment, may increase risk of seizures.
Monitor renal function. Observe for signs and symptoms of anaphylaxis during first dose.
Pregnancy Risk Factor
Ceftazidime crosses the placenta (Jørgensen 1987).
Due to pregnancy-induced physiologic changes, some pharmacokinetic parameters of ceftazidime may be altered (Giamarellou 1983; Jørgensen 1987; Nathorst-Böös 1995).
What is this drug used for?
• It is used to treat bacterial infections.
All drugs may cause side effects. However, many people have no side effects or only have minor side effects. Call your doctor or get medical help if any of these side effects or any other side effects bother you or do not go away:
• Injection site irritation
WARNING/CAUTION: Even though it may be rare, some people may have very bad and sometimes deadly side effects when taking a drug. Tell your doctor or get medical help right away if you have any of the following signs or symptoms that may be related to a very bad side effect:
• Abnormal movements
• Extra muscle movement
• Dark urine
• Yellow skin or eyes
• Change in amount of urine passed
• Not able to pass urine
• Sore throat
• Severe loss of strength and energy
• Clostridioides (formerly Clostridium) difficile-associated diarrhea like abdominal pain or cramps, severe diarrhea or watery stools, or bloody stools.
• Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing, swallowing, or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.
Note: This is not a comprehensive list of all side effects. Talk to your doctor if you have questions.
Consumer Information Use and Disclaimer: This information should not be used to decide whether or not to take this medicine or any other medicine. Only the healthcare provider has the knowledge and training to decide which medicines are right for a specific patient. This information does not endorse any medicine as safe, effective, or approved for treating any patient or health condition. This is only a limited summary of general information about the medicine's uses from the patient education leaflet and is not intended to be comprehensive. This limited summary does NOT include all information available about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to this medicine. This information is not intended to provide medical advice, diagnosis or treatment and does not replace information you receive from the healthcare provider. For a more detailed summary of information about the risks and benefits of using this medicine, please speak with your healthcare provider and review the entire patient education leaflet.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
More about ceftazidime
- Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Interactions
- Compare Alternatives
- Pricing & Coupons
- En Español
- Drug class: third generation cephalosporins
- FDA Alerts (1)